KOD
Kodiak Sciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$91.35
+6.53%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -23.5%
- EBIT
- -18.8%
- EPS
- -10.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -17.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- -36.2%
- EBIT
- -25.4%
- Net income
- -30.5%
- EPS
- -29.0%
- Free cash flow
- -16.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026